Both IDH1 and IDH2 mutations are more frequent in grade II-III gliomas and secondary glioblastoma (70–75%) than in primary glioblastoma (5%) [14], are present at higher frequencies in younger patients, and are associated with a relatively favourable prognosis [13], [15]. This evidence concerns the gene IDH1 and glioma.